Armata’s phage product candidates aim to address areas of significant unmet clinical need, by targeting key antibiotic-resistant bacteria including those on the World Health Organization’s global priority pathogens list. Armata’s lead product candidate, AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. Armata is also developing and advancing a broad pipeline of proprietary synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent are being developed with Merck.
| Pathogen | Indications | Discovery | Preclinical | Phase 1 | Phase 2 |
|---|---|---|---|---|---|
| Staphylococcus aureus | Bacteremia |
AP-SA01
|
|||
| Pseudomonas aeruginosa | Respiratory | ||||
| Undisclosed | Undisclosed |
Partnered
 |
| Pathogen Indications |
Phase | Partner |
|---|---|---|
| S. aureus Bacteremia |
Phase 1/2 (AP-SA01) | |
| P. aeruginosa Respiratory |
Preclinical | |
| Undisclosed Undisclosed |
Discovery | |
